Valrubicin
Valstar (valrubicin) is a small molecule pharmaceutical. Valrubicin was first approved as Valstar preservative free on 1998-09-25. It is used to treat urinary bladder neoplasms in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Valstar (generic drugs available since 2019-04-19)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Valrubicin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VALSTAR PRESERVATIVE FREE | Endo | N-020892 RX | 1998-09-25 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| valstar | New Drug Application | 2020-12-16 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9357 | Injection, valrubicin, intravesical, 200 mg |
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | 5 | 3 | 1 | 10 |
| Postoperative pain | D010149 | G89.18 | — | — | 3 | 2 | 1 | 6 | |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | — | 1 | — | 1 |
| Rupture | D012421 | — | — | — | 1 | — | 1 | ||
| Hyperalgesia | D006930 | — | — | — | 1 | — | 1 | ||
| Sprains and strains | D013180 | — | — | — | 1 | — | 1 | ||
| Low back pain | D017116 | HP_0003419 | M54.5 | — | — | — | 1 | — | 1 |
| Acute pain | D059787 | R52 | — | — | — | 1 | — | 1 | |
| Dysmenorrhea | D004412 | HP_0100607 | N94.6 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | 2 | — | — | 2 |
| Pancreatitis | D010195 | EFO_0000278 | K85 | — | 1 | 1 | — | — | 1 |
| Endoscopic retrograde cholangiopancreatography | D002760 | — | 1 | 1 | — | — | 1 | ||
| Pharyngitis | D010612 | R07.0 | — | — | 1 | — | — | 1 | |
| Hallux valgus | D006215 | HP_0001822 | — | — | 1 | — | — | 1 | |
| Laparoscopic cholecystectomy | D017081 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Platelet aggregation | D010974 | GO_0070527 | — | — | — | — | 1 | 1 | |
| Neoplasms | D009369 | C80 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VALRUBICIN |
| INN | valrubicin |
| Description | Valrubicin is an anthracycline and a trifluoroacetamide. |
| Classification | Small molecule |
| Drug class | antineoplastic antibiotics (daunorubicin type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCCC(=O)OCC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(OC)cccc1C3=O |
Identifiers
| PDB | — |
| CAS-ID | 56124-62-0 |
| RxCUI | 31435 |
| ChEMBL ID | CHEMBL1096885 |
| ChEBI ID | — |
| PubChem CID | 454216 |
| DrugBank | DB00385 |
| UNII ID | 2C6NUM6878 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 677 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
13,894 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more